Ose Immunotherapeutics
Clinical trials sponsored by Ose Immunotherapeutics, explained in plain language.
-
New PD-1 blocker aims to shrink advanced tumors
Disease control Recruiting nowThis study tests a new drug called OSE-279 that blocks PD-1, a protein that can stop the immune system from attacking cancer. It is for people with advanced solid tumors or lymphomas that have not responded to other treatments. The study has three parts: first finding a safe dose…
Phase: PHASE1, PHASE2 • Sponsor: OSE Immunotherapeutics • Aim: Disease control
Last updated May 17, 2026 02:07 UTC
-
New vaccine aims to control lung cancer when immunotherapy fails
Disease control Recruiting nowThis phase 3 trial tests a new treatment called OSE2101 against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that has stopped responding to immunotherapy. The study includes 363 adults who have a specific genetic marker (HLA-A2). The goal i…
Phase: PHASE3 • Sponsor: OSE Immunotherapeutics • Aim: Disease control
Last updated May 14, 2026 12:01 UTC